Tuning Reactivity of Platinum(II) Complexes
Tuning Reactivity of Platinum(II) Complexes Tuning Reactivity of Platinum(II) Complexes
the hydrolysis of the complex, whereas the non-hydrolysable and sterically demanding lipophilic chelating amine (dach) ligand makes the complex less polar. This has been proposed to contribute to a better cellular uptake. 60 In addition, the dach ligand prevents the binding of the DNA repair proteins by pointing into the major DNA groove (Figure 1.6). These adducts shield the inhibition of DNA replication, resulting in apoptosis and cell death. Oxaliplatin and carboplatin both have bidentate leaving groups that reduce the severity of the side effects by slow ligand exchange reaction with plasma proteins. Figure 1.6: DNA adducts formed by oxaliplatin 13 . Sterically Hindered Platinum(II) Complex (ZD0473) One of the main mechanisms of cisplatin-resistance is an increase in intracellular thiol- mediated detoxification by peptides and proteins such as glutathione and metallothionines (see section 1.3.2.5). Cis-ammninedichlorido(2-methylpyridine)Pt(II), (ZD0473) (Figure 1.7) is the first drug to be administered orally. It is sterically hindered platinum(II) complex and is in phase II clinical trials. 61 Crystal structures of the complex have shown that the pyridine ring is tilted at 102.7° with respect to the PtN2Cl2 coordination square-plane. 62 This introduces steric hindrance directly above the platinum coordination plane, limiting the axial attack by the incoming nucleophile to 11
one side of the coordination square-plane. 63 In addition; this steric hindrance makes it less susceptible to deactivation by the S-containing proteins than cisplatin. This is essential in retarding in vivo cellular detoxification reaction by ubiquitous deactivating scavengers like GSH and MT. This feature is also linked to its ability to overcome cisplatin/drug resistance mechanisms. H 3 N N ZD0473 Figure 1.7: Structure of a sterically hindered platinum(II) complex (ZD0473) that circumvents cisplatin resistance. 1.3.3.2 Platinum(IV) Complexes Platinum(II)-based complexes: cisplatin, carboplatin and oxaliplatin are associated with poor saline solubility, high reactivity and therefore, poor bioavailability and lower pharmaco-stability. In addition, these drugs can only be administered intravenously, making them expensive. An oral drug must be neutral, lipophylic, water soluble and stable to survive in the gastrointestinal media. 64 As a result, octahedral Pt(IV) complexes were developed. Notable examples are satraplatin (JM216) (see Figure 1.2), which has entered phase III of clinical trials for the treatment of ovarian and small lung cancers; and LA-12. These complexes display greater advantages that include 12 Pt i. Greater stability to ligand substitution reactions and bioreductive activation which allows a greater proportion of the drug to arrive at its target the DNA. 65 ii. Higher solubility in aqueous solution enables them to be administered orally. iii. Moderate lipophilic properties due to the presence of bulky non-leaving groups enable them to circumvent resistance caused by decreased Pt accumulation. iv. Exhibition of lower nephrotoxicity and neurotoxicity, besides better sensitivity in cisplatin resistant cell-lines than cisplatin. Cl Cl
- Page 1 and 2: Tuning Reactivity of Platinum(II) C
- Page 3 and 4: Declaration This thesis report is b
- Page 5 and 6: Abstract Systematic kinetic and the
- Page 7 and 8: Table of contents Acknowledgements
- Page 9 and 10: 2.5.5 Effect of Non-participating G
- Page 11 and 12: 5.2.1 Chemical and Solutions ......
- Page 13 and 14: 7.2 Experimental Section ..........
- Page 15 and 16: procurements, Messers P. Forder and
- Page 17 and 18: Figure 2.2 Potential energy profile
- Page 19 and 20: Figure 4.6 Concentration dependence
- Page 21 and 22: Figure 6.1 Spectrophotometric titra
- Page 23 and 24: List of Tables Table 2.1 A selectio
- Page 25 and 26: Table 6.4 Summary of rate constants
- Page 27 and 28: TU thiourea DMTU 1,3-dimethyl-2-thi
- Page 30 and 31: Table of Contents-1 Chapter 1 .....
- Page 32 and 33: 1.0 Introduction 1.1 Cancer Disease
- Page 34 and 35: toxic potential. The most well-know
- Page 36 and 37: 1.3.2.2 Cellular Uptake Cisplatin i
- Page 38 and 39: H 3N OH 2 Pt H 3N OH 2 Active Pt(II
- Page 40 and 41: transformational pathways that comp
- Page 44 and 45: 1.3.4 Terpyridine Platinum(II) Comp
- Page 46 and 47: H 3 N Cl Pt NH 3 H 3 N NH 2 (CH 2 )
- Page 48 and 49: 1.4 Kinetic Interest The platinum-b
- Page 50 and 51: 3. The effect of varying the positi
- Page 52 and 53: 17 R. A. Henderson, The Mechanism o
- Page 54 and 55: Altona J. H. van Boom, G. A. van de
- Page 56 and 57: 76 (a)J. Kašpárková, J. Zehnulov
- Page 58 and 59: Table of Contents-2 Chapter Two ...
- Page 60 and 61: List of Tables Table 2.1: A selecti
- Page 62 and 63: The mononuclear Pt(II) complexes 1-
- Page 64 and 65: Potential Energy R + X RX 1 transit
- Page 66 and 67: For the associative mechanism (A),
- Page 68 and 69: the concentration of one of the rea
- Page 70 and 71: k obs , s -1 0.00030 0.00025 0.0002
- Page 72 and 73: k = Ae -Ea/RT 2.14 lnk = lnA - E a
- Page 74 and 75: = 23.76 + R Hence, a plot of ln ⎛
- Page 76 and 77: iii. # Δ V ≈ 10 cm3 mol-1 featur
- Page 78 and 79: conventional methods are classical
- Page 80 and 81: Figure 2.6: Schematic diagram of a
- Page 82 and 83: The light transmitted from the samp
- Page 84 and 85: c. Oxidizability: Ligands that are
- Page 86 and 87: Table 2.1: A selection of n o pt va
- Page 88 and 89: eaction with different nucleophiles
- Page 90 and 91: eaction site from direct attack by
the hydrolysis <strong>of</strong> the complex, whereas the non-hydrolysable and sterically demanding<br />
lipophilic chelating amine (dach) ligand makes the complex less polar. This has been<br />
proposed to contribute to a better cellular uptake. 60 In addition, the dach ligand<br />
prevents the binding <strong>of</strong> the DNA repair proteins by pointing into the major DNA groove<br />
(Figure 1.6). These adducts shield the inhibition <strong>of</strong> DNA replication, resulting in<br />
apoptosis and cell death. Oxaliplatin and carboplatin both have bidentate leaving groups<br />
that reduce the severity <strong>of</strong> the side effects by slow ligand exchange reaction with plasma<br />
proteins.<br />
Figure 1.6: DNA adducts formed by oxaliplatin 13 .<br />
Sterically Hindered <strong>Platinum</strong>(<strong>II</strong>) Complex (ZD0473)<br />
One <strong>of</strong> the main mechanisms <strong>of</strong> cisplatin-resistance is an increase in intracellular thiol-<br />
mediated detoxification by peptides and proteins such as glutathione and<br />
metallothionines (see section 1.3.2.5). Cis-ammninedichlorido(2-methylpyridine)Pt(<strong>II</strong>),<br />
(ZD0473) (Figure 1.7) is the first drug to be administered orally. It is sterically hindered<br />
platinum(<strong>II</strong>) complex and is in phase <strong>II</strong> clinical trials. 61 Crystal structures <strong>of</strong> the complex<br />
have shown that the pyridine ring is tilted at 102.7° with respect to the PtN2Cl2<br />
coordination square-plane. 62 This introduces steric hindrance directly above the<br />
platinum coordination plane, limiting the axial attack by the incoming nucleophile to<br />
11